Compounds > n-(3-iodopropen-1-yl)-2-carbomethoxy-3-(4-chlorophenyl)tropane

n-(3-iodopropen-1-yl)-2-carbomethoxy-3-(4-chlorophenyl)tropane and Nerve-Degeneration

n-(3-iodopropen-1-yl)-2-carbomethoxy-3-(4-chlorophenyl)tropane has been researched along with Nerve-Degeneration* in 1 studies

Other Studies

1 other study(ies) available for n-(3-iodopropen-1-yl)-2-carbomethoxy-3-(4-chlorophenyl)tropane and Nerve-Degeneration

Article	Year
Genetic, clinical, and imaging characterization of one patient with late-onset, slowly progressive, pantothenate kinase-associated neurodegeneration. Movement disorders : official journal of the Movement Disorder Society, 2006, Volume: 21, Issue:3 We report on a patient with late-onset, pantothenate kinase-associated neurodegeneration (PKAN) who revealed two new heterozygous mutations at gene testing and showed asymmetric moderately reduced striatal dopamine transporter binding with single photon emission computed tomography, possibly due to prolonged neuroleptic treatment. These findings expand the genetic and imaging spectrum of this rare disorder. Topics: Age Factors; Brain; Disease Progression; DNA Mutational Analysis; Dopamine Plasma Membrane Transport Proteins; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Molecular Sequence Data; Nerve Degeneration; Phosphotransferases (Alcohol Group Acceptor); Point Mutation; Radiopharmaceuticals; Tomography, Emission-Computed, Single-Photon; Tropanes	2006

Article

Year

Genetic, clinical, and imaging characterization of one patient with late-onset, slowly progressive, pantothenate kinase-associated neurodegeneration.

Movement disorders : official journal of the Movement Disorder Society, 2006, Volume: 21, Issue:3

We report on a patient with late-onset, pantothenate kinase-associated neurodegeneration (PKAN) who revealed two new heterozygous mutations at gene testing and showed asymmetric moderately reduced striatal dopamine transporter binding with single photon emission computed tomography, possibly due to prolonged neuroleptic treatment. These findings expand the genetic and imaging spectrum of this rare disorder.

Topics: Age Factors; Brain; Disease Progression; DNA Mutational Analysis; Dopamine Plasma Membrane Transport Proteins; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Molecular Sequence Data; Nerve Degeneration; Phosphotransferases (Alcohol Group Acceptor); Point Mutation; Radiopharmaceuticals; Tomography, Emission-Computed, Single-Photon; Tropanes

2006